B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
City of Hope Medical Center
M.D. Anderson Cancer Center
Washington University School of Medicine
Case Comprehensive Cancer Center
University of Washington